James Porter is the founder of Nuvalent. Nuvalent has raised $336M in total funding. Latest round: IPO. Backed by Deerfield Management.
James Porter is the founder and CEO of Nuvalent, a clinical-stage biopharmaceutical company focused on developing small-molecule kinase inhibitors for treatment-resistant cancers. He led the company from its founding by Deerfield Management in 2017 through its Series A, Series B, and 2021 IPO. Under his leadership, Nuvalent advanced two oncology programs and is targeting FDA approval for one program in 2026.
Full founder directory · Investor directory · Company funding database · Fundraising library